Cevimeline Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Cevimeline
Therapeutic Class: Cholinergic agonist
Subclass: Muscarinic receptor agonist
Speciality: Rheumatology
Schedule (India): NOT LISTED
Route(s): Oral
Formulations Available in India:
• NOT AVAILABLE in India
• NOT AVAILABLE in India
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
• No approved indications in India — Drug not marketed or registered with CDSCO
Secondary Indications – Adults Only (Off-label, if any)
| Indication | Dosing Details | Notes |
|
Xerostomia in Sjögren’s Syndrome (OFF-LABEL, Specialist-only)
|
Starting dose: 30 mg orally three times daily
|
US FDA-approved for this indication |
|
Titration: Not typically required
|
Supported by RCTs (Fox RI et al., 2002) | |
|
Usual maintenance dose: 30 mg three times daily
|
Used off-label by rheumatology specialists in India via import | |
|
Maximum dose: 30 mg three times daily
|
Evaluate clinical response at 8–12 weeks | |
|
Duration: Chronic use; reassess periodically
|
Exclude drug-induced xerostomia before initiation |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
• Not applicable — No approved paediatric indications in India
Secondary Indications – Paediatric Doses (Off-label, if any)
• Not applicable — No established off-label paediatric use
General Paediatric Statement
| Age Group | Recommendation |
| <18 years | Not recommended |
| Safety/Efficacy | Not established in paediatric population |
| Exception | Use ONLY under strict rheumatology or paediatric specialist supervision if benefit clearly outweighs risk |
RENAL ADJUSTMENT
| eGFR (mL/min) | Recommendation |
| ≥60 | No adjustment required |
| 30–59 | Use with caution; limited pharmacokinetic data |
| <30 | Avoid unless benefits clearly outweigh risks; specialist supervision required |
| Haemodialysis | No data available; avoid use |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
Use with caution; consider starting at lower dose (15 mg TDS) |
|
Moderate impairment
|
Dose reduction advised; close monitoring for adverse effects |
|
Severe impairment
|
Avoid use; if essential, specialist guidance mandatory |
CONTRAINDICATIONS
• Uncontrolled asthma
• Known hypersensitivity to cevimeline or related muscarinic agonists
• Acute iritis
• Narrow-angle glaucoma (uncontrolled)
• Severe hepatic impairment
• Known hypersensitivity to cevimeline or related muscarinic agonists
• Acute iritis
• Narrow-angle glaucoma (uncontrolled)
• Severe hepatic impairment
CAUTIONS
• Controlled asthma or COPD — risk of bronchoconstriction
• Cardiovascular disease — possible bradycardia, hypotension
• Peptic ulcer disease — may increase gastric acid secretion
• History of nephrolithiasis — ensure adequate hydration
• Biliary tract disease
• Cognitive impairment — monitor for worsening symptoms
• Risk of dehydration from excessive sweating
• Cardiovascular disease — possible bradycardia, hypotension
• Peptic ulcer disease — may increase gastric acid secretion
• History of nephrolithiasis — ensure adequate hydration
• Biliary tract disease
• Cognitive impairment — monitor for worsening symptoms
• Risk of dehydration from excessive sweating
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Not recommended — Insufficient human data |
|
Animal Studies
|
Suggest possible embryofetal risk |
|
Preferred Alternatives
|
Pilocarpine (if essential, under specialist care) or non-pharmacologic measures (artificial saliva, hydration) |
|
When Used
|
Only if life-threatening benefit; requires multidisciplinary input |
|
Monitoring
|
Fetal well-being if inadvertent exposure; obstetric and rheumatology co-management |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Not recommended |
|
Excretion in Milk
|
Unknown |
|
Expected Drug Levels
|
Not established |
|
Preferred Alternatives
|
Pilocarpine (limited data) or non-pharmacologic measures |
|
Infant Monitoring
|
If inadvertently exposed — observe for excessive salivation, diarrhoea, feeding difficulties |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
15 mg twice daily (lower than standard adult dose) |
|
Titration
|
Increase cautiously to 30 mg TDS based on tolerance |
|
Special Risks
|
Increased sensitivity to cholinergic effects; higher risk of orthostatic hypotension, bradycardia, dehydration |
|
Monitoring
|
Hydration status, heart rate, blood pressure; falls risk assessment |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
|
β-blockers (atenolol, propranolol, metoprolol)
|
Additive bradycardia and conduction abnormalities | Avoid combination or use with ECG monitoring |
|
Pilocarpine
|
Overlapping muscarinic mechanism; additive toxicity | Do not co-administer |
|
Anticholinergic agents (atropine, hyoscine, ipratropium)
|
Pharmacological antagonism; reduced efficacy of both | Avoid concomitant use |
|
Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion)
|
Increased cevimeline plasma levels | Monitor for cholinergic toxicity; consider dose reduction |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
|
SSRIs (sertraline, escitalopram)
|
Unpredictable effects on saliva production | Monitor therapeutic response |
|
Diuretics (furosemide, hydrochlorothiazide)
|
Increased dehydration risk with excessive sweating | Ensure adequate fluid intake |
|
Antihypertensives (amlodipine, telmisartan)
|
Additive hypotensive effect | Monitor blood pressure |
|
Antipsychotics with anticholinergic properties (olanzapine, clozapine)
|
Antagonise muscarinic effects | May reduce cevimeline efficacy |
|
Drugs causing QT prolongation
|
Theoretical additive risk with bradycardia | Monitor ECG if combination necessary |
COMMON ADVERSE EFFECTS
• Excessive sweating (diaphoresis)
• Nausea
• Rhinitis / nasal congestion
• Headache
• Increased salivation (sialorrhoea)
• Diarrhoea
• Visual disturbances (especially reduced night vision)
• Nausea
• Rhinitis / nasal congestion
• Headache
• Increased salivation (sialorrhoea)
• Diarrhoea
• Visual disturbances (especially reduced night vision)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Action Required |
| Symptomatic bradycardia | Discontinue immediately; cardiac evaluation |
| Bronchospasm | Discontinue; provide bronchodilator therapy |
| Severe dehydration / electrolyte imbalance | Aggressive fluid replacement; discontinue drug |
| Acute narrow-angle glaucoma attack | Ophthalmology emergency; discontinue drug |
| Syncope / severe hypotension | Discontinue; cardiovascular assessment |
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Pulmonary function (if asthma/COPD); blood pressure; heart rate; ophthalmologic examination (if glaucoma risk) |
|
After Initiation (2–4 weeks)
|
Sweating intensity; heart rate; blood pressure; hydration status; symptom response |
|
Long-term (every 3–6 months)
|
Hydration and electrolyte status; periodic eye examination; symptom reassessment; adverse effect review |
BRANDS AVAILABLE IN INDIA
• NOT AVAILABLE in India (as of current data)
PRICE RANGE (INR)
• Not applicable — Drug not marketed in India
• May require import under special license; costs variable and not standardised
• May require import under special license; costs variable and not standardised
CLINICAL PEARLS
• Not approved or marketed in India — procurement requires import under special license via specialist rheumatologist
• Pilocarpine is the preferred salivary stimulant for xerostomia in Sjögren’s syndrome in India due to availability
• Cevimeline has M1/M3 receptor selectivity, potentially offering better tolerability than pilocarpine (fewer GI and cardiac effects)
• Hydration is critical — counsel patients on adequate fluid intake due to sweating-related fluid losses
• Evaluate response by 8–12 weeks; if no improvement, reassess diagnosis and consider alternative management
• Avoid in patients with uncontrolled respiratory disease or visual complaints without ophthalmology clearance
• Pilocarpine is the preferred salivary stimulant for xerostomia in Sjögren’s syndrome in India due to availability
• Cevimeline has M1/M3 receptor selectivity, potentially offering better tolerability than pilocarpine (fewer GI and cardiac effects)
• Hydration is critical — counsel patients on adequate fluid intake due to sweating-related fluid losses
• Evaluate response by 8–12 weeks; if no improvement, reassess diagnosis and consider alternative management
• Avoid in patients with uncontrolled respiratory disease or visual complaints without ophthalmology clearance
TAGS
cevimeline; cholinergic agonist; muscarinic agonist; xerostomia; Sjögren syndrome; dry mouth; NOT available India; rheumatology; off-label; salivary stimulant
VERSION
RxIndia v0.1 — 03 Feb 2026
REFERENCES
• CDSCO — Not approved/registered
• Indian Pharmacopoeia — Not listed
• API Textbook of Medicine — Sjögren’s syndrome management section
• US FDA Prescribing Information (for off-label reference)
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition
• Specialist input — Rheumatology practice patterns in India
• RCT: Fox RI et al., Rheumatology, 2002 — Cevimeline efficacy in Sjögren’s syndrome xerostomia
• Indian Pharmacopoeia — Not listed
• API Textbook of Medicine — Sjögren’s syndrome management section
• US FDA Prescribing Information (for off-label reference)
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition
• Specialist input — Rheumatology practice patterns in India
• RCT: Fox RI et al., Rheumatology, 2002 — Cevimeline efficacy in Sjögren’s syndrome xerostomia
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.